8-K: Black Diamond Reports Strong Silevertinib Phase 2 NSCLC Data

Black Diamond Therapeutics announced positive preliminary Phase 2 data for silevertinib in 1L NSCLC and plans for a new Phase 2 trial in GBM, extending its cash runway into late 2028.

Summary

• Preliminary Phase 2 data for silevertinib in 1L NSCLC patients with non-classical EGFR mutations showed a 60% objective response rate (ORR) and an 86% CNS ORR.
• Among 43 enrolled patients, one confirmed complete response and 25 confirmed partial responses were observed.
• The disease control rate (DCR) was 91%, with 29 patients remaining on therapy, the longest ongoing for over 19 months.
• No new safety signals were observed, and adverse events (AEs) were managed with standard supportive care and dose adjustments without compromising response depth or durability.
• Plans are in place to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed glioblastoma (GBM) patients in the first half of 2026, with preliminary data expected in 2028.
• Cash, cash equivalents, and investments of approximately $135.5 million as of September 30, 2025, are now expected to fund anticipated operating expenses and capital expenditure requirements into the second half of 2028.
• This updated financial guidance assumes the company funds its Phase 2 trial of silevertinib in GBM and that a potential partner funds pivotal development of silevertinib in NSCLC.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary clinical data for silevertinib in NSCLC, particularly its CNS activity, and outlines a clear path for GBM development. The extended cash runway is also a significant positive. The main caveat is the reliance on a partnership for pivotal NSCLC development.

Positives

• Silevertinib achieved a robust 60% objective response rate (ORR) and 91% disease control rate (DCR) in 43 frontline NSCLC patients presenting with 35 unique non-classical EGFR mutations.
• Demonstrated compelling CNS activity with an 86% CNS ORR in NSCLC patients with brain metastases, addressing a critical unmet medical need.
• No new safety signals were observed, and adverse events were manageable with standard supportive care and dose adjustments, maintaining response depth and durability.
• The cash runway has been extended into the second half of 2028, providing significant financial stability.
• Plans to initiate a randomized Phase 2 trial in newly diagnosed GBM patients in 1H 2026, targeting a high unmet need with preclinical data supporting silevertinib's brain penetrance and potency.
• Silevertinib reduces EGFR mutation VAF in ctDNA across 22 unique mutations in 26 patients, achieving 100% clearance in 21 of these patients.

Negatives

• Adverse events experienced by a majority of patients included rash, stomatitis, diarrhea, and paronychia, though these were manageable.
• Pivotal development for silevertinib in NSCLC is contingent on securing a potential partnership, introducing an element of uncertainty regarding its future progression.

Risks

• Actual results may differ materially from forward-looking statements due to inherent risks and uncertainties.
• Risks include those detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.
• The continued development and advancement of silevertinib, including the timing of clinical updates and regulatory feedback, are subject to various risks.
• There is no guarantee that a potential partnership for silevertinib's pivotal development will be secured.
• The company's expected cash runway is based on management's current expectations and assumptions, including the successful funding of NSCLC pivotal development by a partner.

Future Outlook

The company plans to present updated NSCLC Phase 2 results, including Duration of Response (DOR) and Progression-free Survival (PFS) data, in the second quarter of 2026. It continues to explore potential partnerships to advance silevertinib into pivotal development for NSCLC. A randomized Phase 2 trial for silevertinib in newly diagnosed GBM patients is slated to begin in the first half of 2026, with preliminary data anticipated in 2028. The cash runway is extended into the second half of 2028, contingent on a partnership for NSCLC pivotal development.

Management Comments

• "We are pleased to share these initial data in frontline NSCLC patients showing silevertinib's activity against a broad spectrum of 35 distinct non-classical EGFR mutations." Mark Velleca, M.D., Ph.D., President and Chief Executive Officer.
• "We are particularly encouraged by the CNS activity of silevertinib in treating NSCLC patients with brain metastases, as published data clearly demonstrate that CNS metastases are a key factor in early disease progression for NCM NSCLC patients treated with secondand third-generation EGFR-TKIs." Mark Velleca, M.D., Ph.D., President and Chief Executive Officer.
• "These highly encouraging data speak to the potential of silevertinib to be the treatment of choice for frontline NSCLC patients with the full spectrum of non-classical EGFR mutations." Sergey Yurasov, M.D., Ph.D., Chief Medical Officer.
• "We are struck by the compelling CNS response rate, which may translate to prolonged durability of response for patients with CNS metastases." Sergey Yurasov, M.D., Ph.D., Chief Medical Officer.
• "Based on encouraging CNS activity demonstrated by silevertinib across multiple trials, and its preclinical potency on all EGFR alterations found in GBM, we believe that silevertinib has the potential to be the first targeted therapy for these patients." Elizabeth Buck, Ph.D., Chief Scientific Officer.

Industry Context

Silevertinib targets non-classical EGFR mutations in NSCLC and EGFR alterations in GBM, both representing significant unmet medical needs in oncology. Current EGFR-TKIs offer limited benefit for non-classical EGFR mutations, and prior GBM therapies have struggled with poor brain penetrance and potency against diverse EGFR alterations. Silevertinib's demonstrated brain penetrance and broad activity against a spectrum of mutations position it as a potential 'MasterKey' therapy, addressing key limitations of existing treatments like afatinib and osimertinib, particularly in managing CNS metastases.

Comparison to Industry Standards

• Silevertinib's 60% ORR in 1L NSCLC with non-classical EGFR mutations compares favorably to reported median Progression-Free Survival (mPFS) values for afatinib (e.g., 10.6 months in ACHILLES, 7.0 months in ARTICUNO) and osimertinib (e.g., 9.5 months in ACHILLES) in similar patient populations, suggesting a strong initial response profile.
• The 86% CNS ORR for silevertinib in NSCLC patients with brain metastases is particularly robust, addressing a critical area where other EGFR-TKIs often see high rates of CNS progression (e.g., 1L osimertinib and afatinib).
• Silevertinib's tolerability profile, characterized by AEs like rash, stomatitis, diarrhea, and paronychia, is consistent with the EGFR TKI class, indicating a manageable safety profile similar to other approved agents.
• In GBM, silevertinib aims to overcome limitations of prior EGFR-targeted therapies (e.g., gefitinib, erlotinib, osimertinib, depatuximab, dacomitinib, afatinib) which often lacked sufficient brain penetration, potency against complex EGFR mutations like EGFRvIII, or suffered from paradoxical activation. Silevertinib's preclinical data shows potent inhibition of EGFRvIII and other co-expressed alterations, and it has demonstrated pharmacologically relevant brain exposure in GBM tumor tissue.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong clinical data, extended cash runway, and clear development path, potentially increasing company valuation and future revenue prospects.
• Patients (NSCLC): Potential for a new, effective treatment option for non-classical EGFR mutations, especially those with brain metastases, addressing a significant unmet medical need.
• Patients (GBM): Hope for a novel targeted therapy in a disease with very limited treatment options and high unmet need.
• Employees: Increased job security and potential for growth within a company with promising drug candidates.

Next Steps

• Present updated results (Duration of Response and Progression-free Survival data) from the Phase 2 NSCLC trial at a medical meeting in the second quarter of 2026.
• Continue exploring potential partnerships to advance silevertinib into pivotal development for NSCLC.
• Initiate a randomized Phase 2 trial in newly diagnosed GBM patients in the first half of 2026.
• Expect preliminary data from the GBM Phase 2 trial in 2028.

Key Dates

Recommendation

The preliminary Phase 2 data for silevertinib in 1L NSCLC, particularly the high ORR (60%) and exceptional CNS ORR (86%) in a difficult-to-treat patient population with non-classical EGFR mutations, is highly compelling and significantly de-risks the asset. The extended cash runway into 2H 2028 provides ample time for further development and partnership discussions without immediate dilution concerns. The planned Phase 2 trial in GBM, another area of high unmet need, further expands the drug's potential market. While a partnership is needed for pivotal NSCLC development, the strong data makes this more likely. These factors collectively point to a strong upside potential for the stock.

Keywords

oncology, non-small cell lung cancer, NSCLC, glioblastoma, GBM, EGFR mutations, silevertinib, MasterKey therapy, clinical trial, Phase 2, brain penetrant, targeted therapy, BDTX, Black Diamond Therapeutics, cash runway, biopharmaceutical